List view / Grid view
11 December 2014 | By Gilead Sciences
Results describing long-term safety and disease control presented at the 56th American Society of Hematology Annual Meeting...
10 December 2014 | By Bristol-Myers Squibb Company
The Board of Directors of Bristol-Myers Squibb Company declared a quarterly dividend of thirty-seven cents ($0.37) per share on the $.10 par value Common Stock of the corporation...
10 December 2014 | By Janssen
Janssen-Cilag International NV (Janssen) is pleased to announce the presentation of new longer term follow-up data from two IMBRUVICA® (ibrutinib) studies at the American Society of Hematology (ASH) meeting in San Francisco, CA. IMBRUVICA is a first-in-class, once-daily, oral Bruton’s tyrosine kinase (BTK) inhibitor.
10 December 2014 | By Roche
New data demonstrate high prognostic value of Elecsys blood test...
10 December 2014 | By The Royal Society of Medicine
The system that allows patients rapid access to expensive new treatments lacks transparency and penalises small and low-income countries unable to negotiate lower prices with pharmaceutical manufacturers...
9 December 2014 | By Janssen
International Health Partners (IHP) in partnership with Banco Farmaceutico and Action Medeor has launched EURMED; a unique industry collaboration that enables the donation of medicines for disaster relief and humanitarian aid.
9 December 2014 | By Roche
Roche presented data from a first-in-patient study of the novel humanised bispecific antibody ACE910 (RG6013) in hemophilia A patients during the 56th American Society of Hematology (ASH) Annual Meeting...
9 December 2014 | By Eli Lilly and Company
On 8th December 2014, the Scottish Medicines Consortium accepted for use within NHS Scotland Alimta (pemetrexed) monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer (other than predominantly squamous cell histology) in patients whose disease has not progressed immediately following platinum-based chemotherapy...
Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announce that the Phase 3 RA-BEACON study of the investigational medicine baricitinib met its primary endpoint of improved ACR20 response compared to placebo after 12 weeks of treatment.
9 December 2014 | By Ergomed plc
Ergomed plc has announced that Aeterna Zentaris has signed an exclusive licence and technology transfer agreement with Sinopharm A-Think for the Chinese, Hong Kong and Macau markets for zoptarelin doxorubicin which is in Phase 3 development for treating endometrial cancer...
9 December 2014 | By Roche
Presentations include data on Roche’s broad portfolio of hematology medicines as well as emerging investigational agents including ACE910 (RG6013) in hemophilia A...
9 December 2014 | By Boehringer Ingelheim
New data demonstrate that a five-minute infusion of the investigational specific antidote idarucizumab led to immediate, complete and sustained reversal of the anticoagulant effect of Pradaxa® (dabigatran etexilate)...
9 December 2014 | By Novo Nordisk
Novo Nordisk announced a new analysis of phase 3 data demonstrating people with haemophilia A who had the highest annualised bleeding rate (ABR) during initial treatment with NovoEight® (turoctocog alfa) showed the largest reduction in bleeding over the duration of treatment...
9 December 2014 | By Roche
Victory for Scottish NHS patients as SMC accepts Gazyvaro™ (obinutuzumab) for treatment of most common adult leukaemia...
9 December 2014 | By Roche
cobas HIV-1 and HCV assays offer unparalleled performance on cobas 6800/8800 Systems...
